• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

    9/25/24 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NVAX alert in real time by email
    • Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organization
    • Dr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platform

    GAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D).

    Dr. Ruxandra Draghia-Akli

    Dr. Draghia-Akli brings more than 20 years of experience in vaccines and public health to Novavax. Her blend of expertise includes clinical, corporate and policy work and is inclusive of deep relationships both inside and outside the industry. Dr. Draghia-Akli's ability to identify real public health needs and find the intersection with Novavax's unique technology will be critical as the Company transitions to an R&D focus with a new, expanded pipeline that is focused on building partnerships with industry and public health organizations.

    "Ruxandra brings an incredible breadth of expertise to our Executive Leadership team and with her at the helm of our scientific team, Novavax is well-positioned to develop and execute against a new, expanded R&D strategy," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Ruxandra is the right R&D leader for Novavax at this critical time, and we are confident that she can strategically evaluate both our portfolio and the potential of our scientific technology in partnership with our already strong scientific and clinical development teams."

    Dr. Draghia-Akli has experience in both established pharmaceutical and smaller biotechnology companies. She most recently served as Global Head of Global Public Health R&D at Johnson & Johnson where she spearheaded initiatives to accelerate drug discovery and development across several disease areas, including Dengue, tuberculosis, leprosy and coronaviruses. Previously, Dr. Draghia-Akli also served as Vice President, Global Vaccines at Merck where she contributed to advancing innovative vaccines against Ebola, pneumococcal disease and human papilloma virus. She also worked with the European Commission supporting programmatic, legislative, regulatory and policy issues in research and innovation. She also held roles of increasing responsibility and was responsible for securing start-up funding and grants at Advisys, Inc. (now a part of Inovio Pharmaceuticals). Dr. Draghia-Akli focused on research early in her career at Baylor College of Medicine, University Rene Descartes (Paris) and University Carol Davilla (Romania).

    "I'm excited to join Novavax at such a pivotal time to lead R&D efforts as we set the Company up to successfully build upon and deliver an exciting clinical pipeline," said Dr. Draghia-Akli. "There is tremendous potential in Novavax's scientific platform and Matrix-M™ technology, and I'm looking forward to working with the team to expand beyond COVID-19 and push the boundaries of what the Company's technology can do to improve public health."

    Dr. Draghia-Akli has served on numerous boards and committees over her career to help shape thinking on vaccine and public health issues. Currently, she is part of the 100 Days Mission, Science and Technology Expert Group of the International Pandemic Preparedness Secretariat; the Chair, Scientific Advisory Board of INTREPID Alliance; and the Chair, Scientific Advisory Board of Every Cure. Dr. Draghia-Akli received a BS in mathematics and physics from I.L. Caragiale Lycée; an MD from University Carol Davilla; and a PhD in human genetics from University Carol Davilla.

    Dr. Draghia-Akli's predecessor, Filip Dubovsky, MD MPH, retired from the Company in July 2024 and will continue in his Executive Advisor role. Robert Walker, MD, will continue to lead the Novavax Medical Organization as Chief Medical Officer after serving as interim Head of R&D.

    About Novavax

    Novavax, Inc. (NASDAQ:NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

    Forward-Looking Statements

    Statements herein relating to the future of Novavax, its operating plans and prospects, its expectations regarding its clinical pipeline and research and development efforts, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, antigenic drift or shift in the SARS-CoV-2 spike protein, challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for a JN.1 protein-based COVID-19 vaccine or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

    Contacts:

    Investors

    Alex Delacroix

    240-268-2022

    [email protected]

    Media

    Giovanna Chandler

    240-720-7804

    [email protected]

    Novavax logo (PRNewsfoto/NOVAVAX, INC)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-names-dr-ruxandra-draghia-akli-as-new-executive-vice-president-and-head-of-research--development-302257695.html

    SOURCE Novavax, Inc.

    Get the next $NVAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVAX

    DatePrice TargetRatingAnalyst
    8/20/2025$7.00Neutral → Underperform
    BofA Securities
    6/17/2025$6.00Sell
    Citigroup
    2/28/2025$19.00Buy
    BTIG Research
    7/30/2024$8.00Neutral → Underweight
    JP Morgan
    5/10/2024$4.00 → $12.00Underperform → Neutral
    BofA Securities
    5/10/2024Underweight → Neutral
    JP Morgan
    8/9/2023$15.00Neutral → Buy
    B. Riley Securities
    4/20/2023$55.00 → $10.00Outperform → Market Perform
    TD Cowen
    More analyst ratings

    $NVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novavax downgraded by BofA Securities with a new price target

    BofA Securities downgraded Novavax from Neutral to Underperform and set a new price target of $7.00

    8/20/25 8:27:13 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Novavax with a new price target

    Citigroup initiated coverage of Novavax with a rating of Sell and set a new price target of $6.00

    6/17/25 7:50:20 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BTIG Research initiated coverage on Novavax with a new price target

    BTIG Research initiated coverage of Novavax with a rating of Buy and set a new price target of $19.00

    2/28/25 7:28:04 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Rodgers Richard J

    4 - NOVAVAX INC (0001000694) (Issuer)

    6/24/25 6:40:56 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mott David M

    4 - NOVAVAX INC (0001000694) (Issuer)

    6/24/25 6:40:20 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director King Rachel K.

    4 - NOVAVAX INC (0001000694) (Issuer)

    6/24/25 6:39:07 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $NVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $NVAX
    SEC Filings

    View All

    Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

    Total revenue of $239 million in the second quarter of 2025Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval triggered $175 million milestone payment from SanofiCompleted transition of Nuvaxovid™ commercial leadership in the U.S. to Sanofi for the 2025-2026 COVID-19 vaccination season  COVID-19-Influenza-Combination and stand-alone influenza vaccine candidates showed robust immune responses in initial cohort of a Phase 3 trial with new T-cell response data in both Novavax vaccine candidates numerically higher than in the comparator Fluzone HD armUpdated Full Year 2025 Revenue Framework and Financial Guidanc

    8/6/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

    GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, August 6, 2025. Details of the event and replay are as follows: Conference call details: Date: August 6, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: Register Here Dial-in number: (888) 880-3330 (Domestic) or (+1) (646) 357-8766 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can

    7/30/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

    Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administrationPotential for single intranasal or intramuscular dose could differentiate Novavax's vaccine as part of pandemic emergency preparedness efforts GAITHERSBURG, Md., July 24, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza vaccine candidate, leveraging Novavax's recombinant, protein-based nanoparticle technology and Matrix-M® adjuvant, induced robust immune responses by either single or two-dose intranasal (IN) or intramuscular (IM)

    7/24/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NOVAVAX INC (0001000694) (Filer)

    8/6/25 8:04:19 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Novavax Inc.

    10-Q - NOVAVAX INC (0001000694) (Filer)

    8/6/25 7:47:13 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - NOVAVAX INC (0001000694) (Filer)

    6/24/25 6:03:36 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Novavax Appoints Charles Newton to Board of Directors

    GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp

    4/29/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

    Capstone Companies, Inc. (OTCQB:CAPC) announced today the appointment of Brian Rosen as a non-employee director, effective January 20, 2025. Mr. Rosen has extensive experience in marketing, business development, contract negotiation and government relations as well as experience as a member of two public companies' management. He served as Senior Vice President, Global Market Access, Public Policy & Alliances (2021 - 2023), Senior Vice President, Commercial Strategy (2018 - 2021) and Vice President, Market Access, Policy, & Government Affairs (2015 - 2017) with Novavax, Inc. (NASDAQ:NVAX). Before Novavax, Inc., Mr. Rosen served as Chief Policy, Advocacy & Patient Services Officer (2014 -

    1/23/25 9:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

    Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organizationDr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platformGAITHERSBURG, Md., Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D). Dr. Draghia-Akli brings m

    9/25/24 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Financials

    Live finance-specific insights

    View All

    Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

    Total revenue of $239 million in the second quarter of 2025Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval triggered $175 million milestone payment from SanofiCompleted transition of Nuvaxovid™ commercial leadership in the U.S. to Sanofi for the 2025-2026 COVID-19 vaccination season  COVID-19-Influenza-Combination and stand-alone influenza vaccine candidates showed robust immune responses in initial cohort of a Phase 3 trial with new T-cell response data in both Novavax vaccine candidates numerically higher than in the comparator Fluzone HD armUpdated Full Year 2025 Revenue Framework and Financial Guidanc

    8/6/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

    GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, August 6, 2025. Details of the event and replay are as follows: Conference call details: Date: August 6, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: Register Here Dial-in number: (888) 880-3330 (Domestic) or (+1) (646) 357-8766 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can

    7/30/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

    FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

    5/8/25 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/12/24 4:46:17 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    11/4/24 1:19:04 PM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Novavax Inc.

    SC 13G/A - NOVAVAX INC (0001000694) (Subject)

    7/10/24 6:16:55 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care